|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM110274857 |
| 003 |
DE-627 |
| 005 |
20231222153127.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0368.xml
|
| 035 |
|
|
|a (DE-627)NLM110274857
|
| 035 |
|
|
|a (NLM)11112365
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Muto, G
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Adjuvant-induced improvement of glucose intolerance in type 2 diabetic KK-Ay mice through interleukin-1 and tumor necrosis factor-alpha
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.01.2001
|
| 500 |
|
|
|a Date Revised 15.11.2006
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2000 Academic Press.
|
| 520 |
|
|
|a We reported that administration of complete Freund's adjuvant (CFA) improved glucose tolerance test (GTT) results in obese diabetic KK-Ay mice. In this study, we investigated its mechanism. An injection with CFA remarkably improved GTT for more than a week in KK-Ay mice, although insulin response was not changed compared with saline controls. The hypoglycemic effect of insulin was significantly, but partially, potentiated in the CFA-treated mice compared with the controls, suggesting that CFA stimulated insulin-mediated and non-insulin-mediated glucose disposal. Improvement in the GTT with CFA was partially transferable to nontreated mice by peritoneal exudative cells, but not spleen or lymph node cells. Pretreatment with anti-interleukin (IL)-1 alpha and -1 beta antibodies or anti-tumor necrosis factor (TNF)-alpha antibody significantly abrogated the improvement in the GTT with CFA. The results indicate that CFA-induced improvement in glucose intolerance in KK-Ay mice was mediated at least by IL-1 and TNF-alpha
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-1
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a Freund's Adjuvant
|2 NLM
|
| 650 |
|
7 |
|a 9007-81-2
|2 NLM
|
| 700 |
1 |
|
|a Satoh, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Muto, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takahashi, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakazawa, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sagara, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Miyaguchi, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fukuzawa, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qiang, X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sakata, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takizawa, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bando, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Housai, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tamagawa, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Toyota, T
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 97(2000), 3 vom: 01. Dez., Seite 259-65
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:97
|g year:2000
|g number:3
|g day:01
|g month:12
|g pages:259-65
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 97
|j 2000
|e 3
|b 01
|c 12
|h 259-65
|